Review of Concepts in Therapeutic Decision-making in HER2-negative Luminal Metastatic Breast Cancer

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2020 Feb 14

PMID 32052382

Authors

I Alvarez-Lopez

S Bezares

E Dalmau Portulas

E Garcia-Martinez

J A Garcia-Saenz

M Gil-Gil

E Martinez de Duenas

N Ribelles

A Santaballa Bertran

Affiliations

Soon will be listed here.

Abstract

Purpose: Hormone receptor (HR)-positive, Human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) requires a therapeutic approach that takes into account multiple factors, with treatment being based on anti-estrogen hormone therapy (HT). As consensus documents are valuable tools that assist in the decision-making process for establishing clinical strategies and optimize the delivery of health services, this consensus document has been created with the aim of developing recommendations on cretiera for hormone sensitivity and resistance in HER2-negative luminal MBC and facilitating clinical decision-making.

Methods: This consensus document was generated using a modification of the RAND/UCLA methodology, which included the definition of the project and identification of issues of interest, a non-exhaustive systematic review of the literature, an analysis and synthesis of the scientific evidence, preparation of recommendations, and external evaluation with a panel of 64 medical oncologists specializing in breast cancer.

Results: A Spanish panel of experts reached consensus on 32 of the 32 recommendations/conclusions presented in the first round and were accepted with an approval rate of 100% about definition of metastatic disease not susceptible to local curative treatment, definition of hormone sensitivity and hormone resistance in metastatic luminal disease and therapeutic decision-making.

Conclusion: We have developed a consensus document with recommendations on the treatment of patients with HER2-negative luminal MBC that will help to improve therapeutic benefits.

References

Goldhirsch A, Winer E, Coates A, Gelber R, Piccart-Gebhart M, Thurlimann B . Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013; 24(9):2206-23. PMC: 3755334. DOI: 10.1093/annonc/mdt303. View

Cardoso F, Costa A, Senkus E, Aapro M, Andre F, Barrios C . 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol. 2017; 28(1):16-33. PMC: 5378224. DOI: 10.1093/annonc/mdw544. View

Hepp P, Andergassen U, Jager B, Trapp E, Alunni-Fabbroni M, Friedl T . Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial. Anticancer Res. 2016; 36(9):4771-6. DOI: 10.21873/anticanres.11034. View

Tan P, Haaland B, Montero A, Lopes G . A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer. Breast Cancer Res Treat. 2013; 138(3):961-5. DOI: 10.1007/s10549-013-2495-0. View

Martin M, Loibl S, Hyslop T, de la Haba-Rodriguez J, Aktas B, Cirrincione C . Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. Eur J Cancer. 2019; 117:91-98. PMC: 6718694. DOI: 10.1016/j.ejca.2019.06.002. View

Elkins M . Using PICO and the brief report to answer clinical questions. Nursing. 2010; 40(4):59-60. DOI: 10.1097/01.NURSE.0000369871.07714.39. View

Wolff A, Lazar A, Bondarenko I, Garin A, Brincat S, Chow L . Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol. 2012; 31(2):195-202. PMC: 3532391. DOI: 10.1200/JCO.2011.38.3331. View

Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo H . Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019; 380(20):1929-1940. DOI: 10.1056/NEJMoa1813904. View

Klijn J, Blamey R, Boccardo F, Tominaga T, Duchateau L, Sylvester R . Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol. 2001; 19(2):343-53. DOI: 10.1200/JCO.2001.19.2.343. View

10.

von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh F . Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol. 2009; 27(12):1999-2006. DOI: 10.1200/JCO.2008.19.6618. View

11.

Gradishar W, Anderson B, Balassanian R, Blair S, Burstein H, Cyr A . Breast Cancer Version 2.2015. J Natl Compr Canc Netw. 2015; 13(4):448-75. DOI: 10.6004/jnccn.2015.0060. View

12.

Lumachi F, Basso S . Serum tumor markers in patients with breast cancer. Expert Rev Anticancer Ther. 2004; 4(5):921-31. DOI: 10.1586/14737140.4.5.921. View

13.

Wilcken N, Hornbuckle J, Ghersi D . Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev. 2003; (2):CD002747. PMC: 8094405. DOI: 10.1002/14651858.CD002747. View

14.

Klijn J, Beex L, Mauriac L, van Zijl J, Veyret C, Wildiers J . Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst. 2000; 92(11):903-11. DOI: 10.1093/jnci/92.11.903. View

15.

Martin L, Andre F, Campone M, Bachelot T, Jerusalem G . mTOR inhibitors in advanced breast cancer: ready for prime time?. Cancer Treat Rev. 2013; 39(7):742-52. DOI: 10.1016/j.ctrv.2013.02.005. View

16.

Nelli F, Natoli G, Moscetti L, Massari A, DAuria G, Fabbri M . Epirubicin and docetaxel as first-line treatment for hormonal receptor positive metastatic breast cancer: the predictive value of luminal subtype: a retrospective cohort analysis. J Chemother. 2013; 25(2):112-8. DOI: 10.1179/1973947812Y.0000000059. View

17.

Aksoy S, Dizdar O, Altundag K . Definition of postmenopausal status, age of the breast cancer patients and the outcome of aromatase inhibitors treatment. Breast. 2008; 17(5):433-5. DOI: 10.1016/j.breast.2008.05.003. View

18.

Hortobagyi G, Stemmer S, Burris H, Yap Y, Sonke G, Paluch-Shimon S . Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016; 375(18):1738-1748. DOI: 10.1056/NEJMoa1609709. View

19.

Goetz M, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J . MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017; 35(32):3638-3646. DOI: 10.1200/JCO.2017.75.6155. View

20.

Oishi S, Morton S, Moore A, Beck J, Hays R, Spritzer K . Using data to enhance the expert panel process. Rating indications of alcohol-related problems in older adults. Int J Technol Assess Health Care. 2001; 17(1):125-36. DOI: 10.1017/s0266462301104113. View